title: Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
abstract: OBJECTIVE
  The primary objective was to explore the pharmacodynamic changes during transition from rivaroxaban to warfarin in healthy subjects. Safety, tolerability and pharmacokinetics were assessed as secondary objectives.
  
  
  METHODS
  An open label, non-randomized, sequential two period study. In treatment period 1 (TP1), subjects received rivaroxaban 20 mg once daily (5 days), followed by co-administration with a warfarin loading dose regimen of 5 or 10 mg (for the 10 mg regimen, the dose could be uptitrated to attain target international normalized ratio [INR] ≥2.0) once daily (2-4 days). When trough INR values ≥2.0 were attained, rivaroxaban was discontinued and warfarin treatment continued as monotherapy (INR 2.0-3.0). During treatment period 2, subjects received the same warfarin regimen as in TP1, but without rivaroxaban.
  
  
  RESULTS
  During co-administration, maximum INR and prothrombin time (PT) values were higher than with rivaroxaban or warfarin monotherapy. The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone. However, rivaroxaban had the smallest effect on INR at trough rivaroxaban concentrations. Neither rivaroxaban nor warfarin significantly affected maximum plasma concentrations of the other drug.
  
  
  CONCLUSIONS
  The combined pharmacodynamic effects during co-administration of rivaroxaban and warfarin were greater than additive, but the pharmacokinetics of both drugs were unaffected. Co-administration was well tolerated. When transitioning from rivaroxaban to warfarin, INR monitoring during co-administration should be performed at the trough rivaroxaban concentration to minimize the effect of rivaroxaban on INR.
authors.affiliation: Janssen Research & Development, LLC, Titusville, NJ.
authors.forename: Kenneth Todd
authors.initials: KT
authors.lastname: Moore
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ.
authors.forename: William
authors.initials: W
authors.lastname: Byra
authors.affiliation: Janssen Research & Development, LLC, Springhouse, PA, USA.
authors.forename: Seema
authors.initials: S
authors.lastname: Vaidyanathan
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ.
authors.forename: Jaya
authors.initials: J
authors.lastname: Natarajan
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ.
authors.forename: Jay
authors.initials: J
authors.lastname: Ariyawansa
authors.affiliation: Clinical Pharmacology Unit, Janssen Pharmaceutica NV, Antwerp, Belgium.
authors.forename: Hiba
authors.initials: H
authors.lastname: Salih
authors.affiliation: Janssen Research & Development, LLC, Titusville, NJ.
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Turner
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D001530:Belgium; D001777:Blood Coagulation / Q000187:drug effects*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods; D057915:Drug Substitution; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D011517:Prothrombin Time; D018570:Risk Assessment; D000069552:Rivaroxaban / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014859:Warfarin; D000069552:Rivaroxaban
keywords: pharmacodynamic; pharmacokinetic; rivaroxaban; switching; warfarin